沙美特罗替卡松治疗慢性阻塞性肺疾病急性加重期临床研究

目的探讨沙美特罗替卡松治疗慢性阻塞性肺疾病急性加重期疗效。方法将笔者所在医院2012年1月～2012年4月收治的COPD急性加重期患者分为实验组和对照组,对照组患者给予一般治疗,实验组患者在对照组基础上加用沙美特罗替卡松治疗,观察两组患者临床症状改善情况以及SGRQ评分。结果实验组治疗后其喘息、咳嗽、哮鸣音等临床症状改善情况均明显优于对照组(P<0.05),治疗后SGRQ评分明显优于对照组,差异有统计学意义(P<0.05)。结论沙美特罗替卡松对慢性阻塞性肺疾病急性加重期安全有效,可显著改善患者肺功能,值得在临床工作中推广应用。

Clinical research of salmeterol and fluticasone propionate on acute exacerbation of COPD

Objective To investigate the efficacy of salmeterol and fluticasone propionate on acute exacerbation of COPD.Methods Patients of acute exacerbation of COPD in the author's hospital from January 2012 to 2012 years were divided into experimental and control groups,the control group patients were given general treatment,the experimental group of patients were given salmeterol and fluticasone propionate treatment on the basis of the control group,clinical symptoms improvement were observed as well as the SGRQ score.Results Wheezing,coughing,wheezing sound and clinical symptoms of the experimental group were significantly better than the control group(P < 0.05)the SGRQ score was significantly better than the control group after treatment(P < 0.05),the differences were statistically significance.Conclusion Salmeterol and fluticasone propionate is safe and effective to acute exacerbation of COPD,can significantly improve patients' lung function,is worthy of promotion and application.